STOCKHOLM, Sweden, March 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic name) as a treatment for early Alzheimer's...
Hence then, the article about therapeutic goods administration decides not to register lecanemab in australia was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Therapeutic Goods Administration decides not to register lecanemab in Australia )
Also on site :
- U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combined
- Goldfish Is Offering Fans Free Crackers for Tax Day—Here’s How To Claim Yours
- I had a sexual awakening at 43 – and lost my husband because of it